• Type:
  • Category:

BRAIN Biotech AG Deep Dive CRISPR Cas9 2021 | Opportunity with IR



Dive into the World of CRISPR-Cas9 with BRAIN Biotech AG: Transforming Biotechnology for a Sustainable Future


Join Michael Schneiders from BRAIN Biotech AG as he takes you on a captivating journey through the company’s groundbreaking work in industrial biotechnology. In this detailed video, you’ll learn about the company’s two business segments, BioScience and BioIndustrial, and how their robust technology portfolio and comprehensive BRAIN Bioarchive enable them to tackle complex technological challenges.


Discover how their expertise in CRISPR-Cas9 genome editing and innovative product development shape a sustainable future for industries worldwide. Plus, gain insights into their collaborations with Pha 121/Pharvaris, Biotalatysts Ltd., and their commitment to the United Nations Global Compact. Don’t miss this chance to explore the future of biotechnology with BRAIN Biotech AG.

Company Profile

BRAIN Biotech AG (“BRAIN”) is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group’s business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company’s own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.


The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.


As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals.


Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).


BRAIN Biotech AG

Darmstaedter Strasse 34-36
64673 Zwingenberg,Germany

phone +49 6251 9331 86


  • Mega-Trends
  • What´s New at Brain
  • Pha 121 / Pharvaris
  • CRISPR-Cas Genome Editing Tool
  • Incubator: Future Business
  • Biotalatysts Ltd.



Michael Schneiders
IR | BRAIN Biotech AG​



This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

More Company Presentations

More Company Presentations

Reviews for BRAIN Biotech AG Deep Dive CRISPR Cas9 2021 | Opportunity with IR

There are currently no reviews for BRAIN Biotech AG Deep Dive CRISPR Cas9 2021 | Opportunity with IR
Scroll to top